Trials are in progress in China on monotherapy, and the combination of zanubrutinib with TPO and steroids in refractory ITP patients or first-line therapy (NCT05279872, NCT05369377, NCT05369364). The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.